US Archives - Page 42 of 100 - European Medical Journal

Can Pediatric AD Disease Course Be Changed?

Join experts Amy Paller and Peter Lio for this interactive learning experience.

Data-Driven Approaches to Transgender Healthcare Practices

A state-of-the-art review emphasizes the critical role of data and trust in enhancing healthcare for transgender and gender-diverse (TGD) patients.

Reducing Heart Risks in Arthritis: The Role of TNF Inhibitors

Inflammation is increasingly recognized as a pivotal factor in the development of atherosclerosis and its associated thrombotic complications.

Unpacking the Skin Microbiome: Richard Gallo

AMJ is delighted to welcome Richard Gallo, Professor and Chair of Dermatology at the University of California San Diego, USA. A leading…

Unveiling Hidden Factors in Childhood Asthma Management

The importance of addressing environmental exposures, social determinants of health, and risk-taking behaviors in managing childhood asthma was emphasized in a recently published study by authors from University of Colorado School of Medicine and Children’s Hospital Colorado.

Minimal Monitoring HCV Treatment Improves QoL for Patients

A recent global study found significant improvements in health-related quality of life (HQoL) among individuals with Hepatitis C (HCV) treated with direct-acting antivirals (DAAs) under a minimal monitoring (MINMON) approach.

Patient Perceptions of AI in Dermatology: Narrative Review

Artificial intelligence (AI) is becoming a key tool in skin cancer diagnosis, but patient acceptance remains a critical aspect of its implementation.

New McDonald Criteria Expand MS Diagnoses: ACTRIMS 2025

New findings presented at the ACTRIMS Forum 2025 highlight how the latest revisions to the McDonald Criteria could reshape the diagnosis of multiple sclerosis (MS), allowing for earlier identification in patients with radiologically isolated syndrome (RIS) and atypical clinical presentations.

Ketogenic Diet Modulates Immune Function in MS: ACTRIMS 2025

At the ACTRIMS Forum 2025 in West Palm Beach, Florida, researchers unveiled compelling findings on the effects of a 6-month modified Atkins diet (MAD), a less restrictive form of the ketogenic diet, on patients with relapsing multiple sclerosis (MS).

Tolebrutinib Targets Chronic Lesions in MS Treatment: ACTRIMS 2025

A new analysis of Phase III clinical trial data presented at the ACTRIMS Forum 2025 in West Palm Beach, Florida, suggests that tolebrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), may be effective in multiple sclerosis (MS) with chronic active lesions.